Table 1.
Patient and tumour characteristics
| Before NAC (N = 74) | After NAC (N = 64) | |
|---|---|---|
| Age,years | 50.8 ± 8.35 | 52.66 ± 8.95 |
| Tumour size | ||
| T1 | 2 (2.7%) | 46 (71.9%) |
| T2 | 36 (48.6%) | 14 (21.9%) |
| T3 | 31 (41.9%) | 4 (6.3%) |
| T4 | 5 (6.8%) | 0 (0%) |
| Lymph node | ||
| pN0 | 20 (27.0%) | 46 (71.9%) |
| pN1 | 42 (56.8%) | 16 (25.0%) |
| pN2-3 | 12 (16.2%) | 2 (3.1%) |
| Subtype (IHC) | ||
| TNBC | 20 (27.0%) | 16 (25.0%) |
| HER2+ | 34 (45.9%) | 32 (50.0%) |
| HR+, HER2− | 20 (27.0%) | 16 (25.0%) |
| Regimens of NAC | ||
| TCb | 20 (27.0%） | 16 (25.0%） |
| THP | 34 (45.9%） | 32 (50.0%） |
| AC-T | 20 (27.0%） | 16 (50.0） |
| Axillary surgery type | ||
| SLND | 12 (16.2%) | 12 (18.8%) |
| ALND | 52 (70.2%) | 52 (71.2%) |
| Unknown | 10 (13.8%) | 0 (0%) |
| Total | 74 (100%) | 64 (100%) |
AC-T,adriamycin with cyclophosphamide plus docetaxel;ALND, axillary lymph node dissection; HER2, Human epidermal growth factor receptor; HR, Hormone receptor;IHC, Immunohistochemical; NAC, Neoadjuvant chemotherapy;SLNB, sentinel lymph node biopsy; TCb,Docetaxel with carboplatin;THP,Docetaxel with Trastuzumab andPertuzumab; TNBC, Triple negative breast cancer.